Loading data for CING — first visit, this takes a few seconds.
Cingulate Inc. (CING)
NasdaqCM: CING
· 实时价格 · USD
5.02
-0.15 (-2.90%)
收盘价： Sep 11, 2026, 8:00 PM
5.02
+0.00%
盘后: 4:10 PM
股价、关键数字和最新消息，都在这一页。
Cingulate Inc.（CING）股价、分析与数据
暂无数据
| 买价 | 3.71 |
| 市值 | 73M |
| 营收（TTM） | n/a |
| 净利润（TTM） | -28.8M |
| -0.89 | |
| -3.56 | |
| n/a | |
| -5.7 | |
| 市净率（TTM） | 2.97 |
| 市销率（TTM） | 0.00 |
| 财报日期 | n/a |
| 卖价 | 6.75 |
| 成交量 | 94,449 |
| 20日均量 | 220,216 |
| 开盘价 | 5.19 |
| 前收盘价 | 5.17 |
| 日内区间 | 5.02 - 5.28 |
| 52周区间 | 3.16 - 11.89 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
公司完整简介财报意外
Cingulate 已于 Aug 13, 2026 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -0.45 超出预期 0.11, ， 58.72% 同比增长.
